News

Metabolism Based Diagnosis and Precision Medicine for Autism Spectrum Disorders

Read More

New Metabolic Biomarkers Open Door to Earlier Diagnosis, More Precise and Individualized Treatment of Children at Risk for Autism

Read More

Getting Personal with Precision Medicine – PharmaVOICE

Read More

New Quantitative Approach to Autism Diagnosis – IEEE Pulse

Read More

NeuroPointDX to Present New Data from the Children’s Autism Metabolome Project (CAMP) at INSAR

Read More

Metabolism-Based Diagnosis and Precision Medicine for Autism Spectrum Disorders – National TACA Autism Conference – East Coast 2019

Read More

NeuroPointDX to Present Precision Medicine Approaches to Diagnosing and Treating Autism at National TACA Autism Conference

Read More

NeuroPointDX Names E. Robert Wassman, M.D. as Medical Director

Read More
NeuroPointDX Announces Commercialization of First Objective Blood Test to Aid Earlier Diagnosis of Autism Spectrum Disorder

NeuroPointDX Announces Commercialization of First Objective Blood Test to Aid Earlier Diagnosis of Autism Spectrum Disorder

Read More

NeuroPointDX Appoints Noted Neurodevelopmental Expert, Marvin Natowicz, M.D., Ph.D. to Its Scientific Advisory Board

Read More

© 2020 NeuroPointDX All rights reserved. CLIA #: 52D2122420

Powered by Stemina Biomarker Discovery